discovering new anti-infectives
through deep phenotypic insights and machine learning
The "silent pandemic" is no longer silent.
Antimicrobial resistance (AMR) leading to drug-resistant infections is now a recognized and growing global health crisis. The limited pipeline of new drugs to treat the increase in drug resistant infections is a significant global concern.
Discovering new classes of anti-infectives to overcome drug resistant infections.
Our machine learning (ML)-based imaging platform for anti-infective drug discovery enables rapid and highly efficient identification of compounds with new and unexploited mechanisms of action at the very outset of the discovery process.
Our combined expertise, cutting edge technologies and novel workflows enable a rapid and early understanding of a compound’s mechanism of action, the potential addressable target product profile, and clinical utility based on deep analysis of cell behavior.Explore Platform
Delivering new classes of anti-infectives.
ArrePath is applying its technology platform to develop a pipeline of new classes of antibiotics,
targeting unexploited and under-exploited mechanisms of action, to address unmet clinical need and overcome drug resistance.
Recent News and Updates
ArrePath will be attending the seventh annual CytoData meeting, hosted by the Allen Institute for Cell Science, which will take place October 17-20, 2022 in Seattle, Washington.08-25-2022
ArrePath is attending the World Anti-Microbial Resistance Congress taking place on September 7-8, 2022, in National Harbor, MD.08-08-2022
Join ArrePath at 2022 NeurIPS, a premier conference on Machine Learning and AI. This event is taking place at the New Orleans Convention Center on Monday, November 28th – Friday, December 9th.08-01-2022